C4 Therapeutics, Inc. — Director's Dealing 2021

Jun 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: C4 Therapeutics, Inc. (CCCC)
CIK: 0001662579
Period of Report: 2021-06-21

Reporting Person: White Lauren (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-21	Stock Option (Right to Buy)	$38.49	A	136000	Acquired	2031-06-20	Common Stock (136000)	Direct

Footnotes

F1: 25% of this option shall vest and become exercisable on June 21, 2022, with the remainder vesting in 36 equal monthly installments thereafter.